Dosing regimen for anti-DLL3 agents

The present invention provides a method for the treatment of DLL3-positive cancer or SCLC, comprising administering to a subject in need thereof an anti-DLL3 agent at a dose of between about 0.3 mg to about 100 mg or between about 3 mg to about 200 mg, once every two weeks. Step dosing of the anti-D...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	YAGO, MARC ANTHONY, LIAO, MICHAEL, HASHEMI SADRAEI, NOOSHIN, SMIT, MARIE-ANN DAMIETTE, UPRETI, VIJAY VISHESH, NGARMCHAMNANRITH, GATAREE, SOMAN, NEELESH, MINOCHA, MUKUL, SHETTY, ADITYA
Format:	Patent
Sprache:	chi ; eng
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention provides a method for the treatment of DLL3-positive cancer or SCLC, comprising administering to a subject in need thereof an anti-DLL3 agent at a dose of between about 0.3 mg to about 100 mg or between about 3 mg to about 200 mg, once every two weeks. Step dosing of the anti-DLL3 agent for the treatment of SCLC is also disclosed.